Compare AYI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYI | ABVX |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.0B |
| IPO Year | N/A | N/A |
| Metric | AYI | ABVX |
|---|---|---|
| Price | $373.00 | $142.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $395.17 | $115.83 |
| AVG Volume (30 Days) | 261.7K | ★ 1.8M |
| Earning Date | 01-08-2026 | 08-11-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.53 | N/A |
| Revenue | ★ $4,345,600,000.00 | $6,231,374.00 |
| Revenue This Year | $10.96 | $6.80 |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | ★ 13.14 | N/A |
| 52 Week Low | $216.81 | $4.77 |
| 52 Week High | $379.17 | $148.83 |
| Indicator | AYI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 65.24 |
| Support Level | $348.94 | $108.53 |
| Resistance Level | $374.27 | $148.83 |
| Average True Range (ATR) | 8.66 | 7.47 |
| MACD | 0.52 | 2.18 |
| Stochastic Oscillator | 83.98 | 84.29 |
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.